Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis.
Reichenspurner
H
H
Department of Cardiothoracic Surgery and Medicine, Stanford University, California, USA.
Gamberg
P
P
Nitschke
M
M
Valantine
H
H
Hunt
S
S
Oyer
P E
PE
Reitz
B A
BA
D000328:Adult; D000336:Aerosols; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000453:epidemiology / Q000517:prevention & control*; D002177:Candidiasis / Q000453:epidemiology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D016027:Heart Transplantation; D016041:Heart-Lung Transplantation; D006801:Humans; D015994:Incidence; D016040:Lung Transplantation; D008297:Male; D011183:Postoperative Complications; D013997:Time Factors
D000336:Aerosols; D000935:Antifungal Agents; D000666:Amphotericin B